Home » Newsletters » BioWorld

BioWorld

Feb. 25, 1992

View Archived Issues

TSI SHARES ELIGIBLE FOR CONVERSION

CAMBRIDGE BIO ENTERS PRIVATE LABEL PACT

ONCOTECH TO DEVELOP IMUVERT

CIBA TO TEST APHTON IMMUNE STIMULANTS

MEDICIS WARRANT REDEMPTION RAISES $14M

MYCOGEN ADOPTS POISON PILL

SOMATOGEN BLOOD SUBSTITUTE ENTERS TRIALS

ICOS BACK TO THE FUNDING WELL

GRANT FOR DNA IDENTIFICATION SYSTEM

MGI FILES FOR SALAGEN APPROVAL

RISK POLICY PAVES WAY FOR BIOTECH RULES

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 1, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026